Back to Studies

Study analysis · Frontiers in Nutrition · 2022

Fish oil pills slashed inflammation in smokers by 23%—and the effect lasted for HALF A YEAR after they stopped taking them.

Taking big fish oil pills for six months made a key inflammation marker drop by 23% in heavy smokers, and the benefit stuck around for six more months after they stopped.

Reading level
Moderate certainty
Level 1b · Individual RCT

Overview

What the study found

The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.

In simple terms

This study gave people who smoked a lot a special fish oil pill and saw that their body’s inflammation markers went down. But it didn’t test if they got less sick or lived longer — just that some blood numbers changed. So we know the pill changed those numbers, but we don’t know if it actually made them healthier in the long run.

What’s the bottom line?

Scientists tested if taking big fish oil pills daily for six months could reduce inflammation in people who smoke or used to smoke heavily.

How strong is this study?

The study did a good job randomly giving people either the pill or nothing, which helps us know the pill caused the changes. But nobody was blind to who got the pill, so people might have felt better just because they thought it worked. Also, some people dropped out, and the pill stayed in their bodies too long — so the results aren’t perfect, but still pretty strong for a single study.

Reporting

40 / 100

  • COI disclosure+40/40
  • Data availabilitydata not shared
  • Code availabilitycode not shared
Methodology

62 / 100

  • Randomization+20/20
  • Blindingnot blinded
  • Control group+15/15
  • Sample size (n=49)+4.3/20
  • Follow-up+10/10
Publication

100 / 100

Statistical

77 / 100

  • P-values+15/15
  • Effect size+20/20
  • Confidence intervalsno confidence intervals
  • Pre-registration+15/15

Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.

Where it sits

RCT reviews

Max 100

Randomized Trials

Max 90

Reviews of Cohort Studies

Max 85

Cohort Studies

Max 72

Reviews of Case-Control Studies

Max 63

Case-Control Studies

Max 58

Cross-Sectional & Case Series

Max 50

Expert Opinion

Max 5
StrongerWeaker
Randomized Trials
Level 1b
69

69 / 100

Probability of being correct

Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.

This design can establish causation. Although this is a randomized controlled trial, the lack of blinding introduces performance and detection bias, which may inflate effect estimates. The crossover design with insufficient washout period and unequal group sizes at the second phase further limit causal inference strength.

No Conflicts

No conflicts of interest identified

No conflicts of interest or funding sources are disclosed in the text; study appears independently conducted with no industry ties evident.

Independent Analysis Safeguards

  • Blood samples were analyzed after all participants completed enrollment
  • Assays were performed using standardized commercial kits with manufacturer instructions
  • Statistical analysis was pre-specified with power calculation based on prior study data
  • Randomization was conducted via sealed envelopes managed by a project manager

The study was approved by the University of British Columbia and BC Cancer ethics board, but no funding sources, industry sponsors, or author financial disclosures are mentioned. The omega-3 supplement was provided as 'Webber Triple Strength', but no information is given about whether Webber funded the study or had any role in design or analysis. Absence of disclosure raises potential transparency concerns, but no evidence of bias or conflict is present in the reported methods or results.

Key takeaways

  1. 01

    After six months, CRP (inflammation marker) dropped by 23%, PGE2 dropped by 20–30%, and immune cells shifted to less inflammatory types.

  2. 02

    These changes lasted six months after stopping the pills.

  3. 03

    Yes — a 23% drop in CRP is similar to a powerful drug used to lower cancer risk, suggesting this could be meaningful for health.

Surprising findings

  • CRP dropped by 23% even though there was no correlation between plasma or RBC omega-3 levels and the CRP reduction.It’s counterintuitive—more omega-3 in the blood didn’t mean more inflammation reduction. This suggests individual biology, not dosage, drives the effect.
  • DHA levels in cell membranes stayed high for six months after stopping, while plasma levels dropped within a month.Most people assume supplements only work while you’re taking them. This shows omega-3 can rewire your cells long-term.
  • Omega-3 didn’t reduce IL-6 or TNF-alpha—even though those are the cytokines most commonly targeted in inflammation studies.This contradicts decades of assumptions that omega-3 broadly suppresses cytokines. It’s selective, not universal.

Practical takeaways

If you’re a heavy smoker or former smoker with high CRP (>2 mg/L), try 3.6g/day of EPA+DHA for 6 months—preferably with higher DHA content.

Effects were only seen in high-risk smokers with elevated inflammation; no benefit was shown for healthy people or other cytokines. Also, 20% dropout due to COVID suggests real-world adherence may be low.

medium confidence

If you have a higher BMI, consider increasing your omega-3 dose—EPA absorption drops with higher body weight, but DHA doesn’t.

This is based on a single correlation in a small study. No dose adjustment guidelines exist yet.

low confidence

Don’t expect omega-3 to lower IL-6 or TNF-alpha—this study shows it’s not a universal anti-inflammatory.

Other studies may show different results in different populations (e.g., metabolic syndrome). Context matters.

high confidence

Why this study matters

CRP Drop = Drug-Level Effect

High-dose omega-3 (3.6 g/day EPA+DHA) reduced C-reactive protein (CRP) by 23% in heavy smokers—a reduction comparable to the cancer-risk-lowering drug canakinumab, which costs over $100,000 per year. The effect size was medium (Cohen’s d = 0.56), and it persisted for six months after stopping supplementation.

This suggests a cheap, accessible supplement could deliver inflammation-lowering power similar to a multi-billion-dollar biologic drug—without the side effects or price tag.

DHA Stays in Your Cells for Months

While plasma omega-3 levels returned to baseline within a month after stopping, DHA levels in red blood cell membranes remained elevated for at least six months—suggesting long-term cellular incorporation. This was not seen with EPA.

Your cells remember the fish oil—even after you stop taking it. This could mean less frequent dosing is possible, or that timing matters more than we thought.

It Only Works on Two Inflammation Markers

Despite reducing CRP and PGE2 by 20–30%, omega-3 had no significant effect on IL-6, TNF-alpha, LTB4, or 35 other cytokines tested—making its anti-inflammatory action highly selective, not broad.

This contradicts the idea that omega-3 is a universal anti-inflammatory. It’s more like a sniper than a shotgun—targeting only specific pathways.

BMI Blocks EPA Absorption

Higher BMI was linked to lower EPA incorporation into red blood cell membranes—suggesting heavier individuals may need higher doses to get the same benefit. DHA absorption wasn’t affected by BMI.

One-size-fits-all omega-3 dosing might be flawed. Your weight could determine whether it works—or doesn’t.

Want the whole report?

Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.